Business
Premier Biomedicals Research on its Patent Pending Anti-Cancer Treatment With Metronomic Chemotherapy Recognized for Publication in the Prestigious British Journal of Cancer
Premier Biomedicals Research on its Patent Pending Anti-Cancer Treatment With Metronomic Chemotherapy Recognized for Publication in the Prestigious British Journal of Cancer.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n \n \n Premier Biomedicals Research on its Patent Pending Anti-Cancer Treatment With Metronomic Chemotherapy Recognized for Publication in the Prestigious British Journal of Cancer\n \n \nPremier Biomedicals Research on its Patent Pending Anti-Cancer Treatment With Metronomic Chemotherapy Recognized for Publication in the Prestigious British Journal of Cancer\n \n EL PASO, TX--(Marketwired - Dec 6, 2016) -  Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for pain management, announced today that a paper describing their groundbreaking metronomic cancer therapy work in conjunction with development of a patent pending CTLA4 anti-cancer antibody drug at the University of Texas El Paso (UTEP) has been accepted for publication by the prestigious British Journal of Cancer.\n The paper, titled, \"Impact of CTLA-4 Blockade In Conjunction With Metronomic Chemotherapy On Preclinical Breast Cancer Growth\" was co-authored by a team of UTEP researchers led by Dr. Giulio Francia in consultation with Dr. Mitchell Felder, Chairman of Premier Biomedical's Scientific Advisory Board. The initial research on this topic was previously presented at the American Association for Cancer Research symposia in April, 2014 and again (updated) in April, 2016.\n William A. Hartman, President and CEO of Premier Biomedical, stated, \"We are pleased that this paper documenting our joint work with UTEP has been recognized as a significant contribution to the understanding and treatment of cancer by such a prestigious publication as the British Journal of Cancer. In addition to our joint work with UTEP on metronomic chemotherapy, our patent pending anti-cancer antibody drug not only outperformed standard chemo, but also outperformed the leading commercially available anti-cancer drug in initial animal tests. We are presently engaged in the antibody humanization process over the next 4-6 months and will commence further testing at that time.\"\n About The British Journal of Cancer.\n The British Journal of Cancer (BJC) is a multidisciplinary journal of cancer research. It is published twice monthly and is recognized...